Geoffrey S. Ginsburg, M.D., Ph.D. is the founding Director of the Center for Genomic Medicine in the Duke Institute for Genome Sciences & Policy. He is also Professor of Medicine and of Pathology at Duke University Medical Center. Dr. Ginsburg received his M.D. and Ph.D. in biophysics from Boston University. He completed an internal medicine residency at Beth Israel Hospital in Boston. Subsequently, he pursued postdoctoral training in clinical cardiovascular medicine at Beth Israel Hospital and in molecular biology at Children’s Hospital as a Bugher Foundation Fellow of the American Heart Association. In 1990 he joined the faculty of Harvard Medical School where he was Director of Preventive Cardiology and led a laboratory in applied genetics of cardiovascular disease. In 1997, Dr. Ginsburg joined Millennium Pharmaceuticals, Inc., as Senior Program Director for Cardiovascular Diseases. In 2000, he was appointed Vice President of Molecular and Personalized Medicine at Millennium, where he was responsible for developing pharmacogenomic strategies for therapeutics, as well as biomarkers for disease and their implementation in the drug development process. He assumed his current position in the Duke Institute for Genome Sciences & Policy in September 2004. Dr. Ginsburg has received a number of awards for his research accomplishments, including the Innovator in Medicine Award from Millennium in 2004 and the Basic Research Achievement Award in Cardiovascular Medicine from Duke in 2005. He is a founding member of the Personalized Medicine Coalition, an Associate Editor for The Journal of the American College of Cardiology, and an Associate Editor for Genomic Medicine. He has been an international expert panel member for Genome Canada and is currently a member of: the Board of External Experts for the NHLBI, the Secretary of Veterans Affairs Advisory Council on Genomic Medicine, the Institute of Medicine’s Roundtable on Genome Based Research to Human Health. Recently, he was appointed to the Food and Drug Administration's Clinical Pharmacology Advisory Council. His research interests are in the development of novel paradigms for developing and translating genomic information into medical practice and the integration of personalized medicine into health care.